FDA Approves Lenalidomide as Maintenance Therapy for Patients With Multiple Myeloma
On February 22, 2017, the U.S. Food and Drug Administration (FDA) approved lenalidomide (Revlimid®, Celgene Corp.) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
Statin Use May Improve Overall Survival From Multiple Myeloma
A new study has found that use of statin medications in patients with multiple myeloma was associated with a decreased risk of all-cause and cancer-specific mortality. The findings were published in the Journal of Clinical Oncology.